AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RACE ONCOLOGY LTD

0.960

+0.0353.78%

Volume:85.28K

Turnover:82.08K

Market Cap:166.77M

PE:-21.23

High:1.000

Open:0.925

Low:0.925

Close:0.925

Loading ...

Overview Company News Filings

Race Oncology Begins Patient Enrollment at Second Site of RC220 Solid Tumor Clinical Trial

MT Newswires Live

Race Oncology Begins Patient Enrollment in Australia for RC220 Phase 1 Clinical Trial; Shares Up 6%

MT Newswires Live

Race Oncology Obtains Human Ethics Approval for Phase 1 Clinical Trial at Gosford, Wyong Hospitals in New South Wales

MT Newswires Live

Friday’s HotCopper Trends: Race kicks off trials, Tivan in Timor-Leste | March 14, 2025

The Market Herald

Race Oncology Receives Ethics Committee's Nod for Phase 1 Trial of Cancer Treatment Drug Candidate; Shares Rise 9%

MT Newswires Live

Race Oncology approved for Phase I trial for chemotherapeutic treatments

The Market Herald

Race Oncology's (ASX:RAC) investors will be pleased with their stellar 240% return over the last five years

Simply Wall St.

Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development

MT Newswires Live

BRIEF-Race Oncology Executes A$8.6M Contract

Race Oncology Ltd - Race Executes a$8.6M Contract to Support Phase 1 Trial of Rc220 in Solid Tumour Patients

THOMSON REUTERS

3 ASX Penny Stocks With Market Caps Larger Than A$100M To Watch

Simply Wall St.

Orix's Stake Sale in Greenko Energy to Provide Additional Capital, S&P Says

MT Newswires Live

ASX Market Close: Index pares gains as Bitcoin cracks US$100,000 | December 5, 2024

The Market Herald

3 ASX biotech shares rocketing 10% to 26% on BIG news!

Race Oncology Files Ethics Application for Solid Tumor Trial; Shares Rise 9%

MT Newswires Live

Queensland Pacific Metals' Unit Finalizes Contracts for Power Station, Gas Pipeline; Shares Rise 4%

MT Newswires Live

ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest

2 ASX healthcare shares having a stellar run today

ASX Market Update: Index pares gains to trade flat in the afternoon | November 21, 2024

The Market Herald

Race Oncology Completes Drug Discovery Program at Monash University; Shares Up 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","market":"AU","secType":"STK","nameCN":"RACE ONCOLOGY LTD","latestPrice":0.96,"timestamp":1745302320000,"preClose":0.925,"halted":0,"volume":85281,"delay":0,"nameEN":"RACE ONCOLOGY LTD","floatShares":120103231,"shares":173721858,"eps":-0.045225,"marketStatus":"Closed","change":0.035,"latestTime":"04-22 16:12:00 AEST","open":0.925,"high":1,"low":0.925,"amount":82078,"amplitude":0.081081,"askPrice":0.995,"askSize":17000,"bidPrice":0.96,"bidSize":3997,"shortable":3,"etf":0,"ttmEps":-0.045225,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.925,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.619987,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAC.AU\",,,,,undefined,":{"symbol":"RAC.AU","floatShares":120103231,"roa":"-24.05%","roe":"-37.20%","lyrEps":-0.084007,"volumeRatio":0.619987,"shares":173721858,"dividePrice":0,"high":1,"amplitude":0.081081,"preClose":0.925,"low":0.925,"week52Low":0.92,"pbRate":"8.05","psRate":"31.74","week52High":2.09,"institutionHeld":0,"latestPrice":0.96,"committee":-0.619279,"eps":-0.045225,"divideRate":0,"volume":85281,"delay":0,"ttmEps":-0.045225,"open":0.925,"prevYearClose":1.35,"prevWeekClose":0.925,"prevMonthClose":1.065,"prevQuarterClose":1.065,"fiveDayClose":1.02,"twentyDayClose":1.165,"sixtyDayClose":1.245},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529284350","title":"Race Oncology Begins Patient Enrollment at Second Site of RC220 Solid Tumor Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529284350","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529284350?lang=en_us&edition=fundamental","pubTime":"2025-04-22 07:48","pubTimestamp":1745279337,"startTime":"0","endTime":"0","summary":"Race Oncology  has opened patient enrollment at the second site of its phase one clinical trial for cancer drug candidate RC220, according to a Tuesday filing with the Australian bourse.The second trial site is at the Central Coast Local Health District in New South Wales.It will use ascending doses of RC220 in up to 33 patients in stage one to assess its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin, and effects on a range of clinical biomarkers.Race Oncology is studying RC220 in combination with doxorubicin in patients with advanced solid tumors. The phase one trial will be conducted at multiple sites across Australia, Hong Kong, and South Korea, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7067","RAC.AU","XJO.AU","XKO.AU","BK7508"],"gpt_icon":0},{"id":"2524299426","title":"Race Oncology Begins Patient Enrollment in Australia for RC220 Phase 1 Clinical Trial; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524299426","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524299426?lang=en_us&edition=fundamental","pubTime":"2025-04-03 08:19","pubTimestamp":1743639566,"startTime":"0","endTime":"0","summary":"Race Oncology  began patient enrollment at Southside Cancer Care Center in Miranda, New South Wales for the Phase 1 clinical trial of RC220 in advanced solid tumors, according to a Thursday filing with the Australian bourse.It will use ascending doses of RC220 in up to 33 patients to determine the safety, tolerability, pharmacokinetics, maximum tolerated combined dose in combination with doxorubicin, and effects on a range of clinical biomarkers, the filing stated.The open-label phase one trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, per the filing.Race Oncology's shares were up 6% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","XAO.AU","BK7067","XKO.AU","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2524903795","title":"Race Oncology Obtains Human Ethics Approval for Phase 1 Clinical Trial at Gosford, Wyong Hospitals in New South Wales","url":"https://stock-news.laohu8.com/highlight/detail?id=2524903795","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524903795?lang=en_us&edition=fundamental","pubTime":"2025-04-01 06:03","pubTimestamp":1743458612,"startTime":"0","endTime":"0","summary":"Race Oncology  received approval from the Bellberry Human Research Ethics Committee to start its RC220 Phase 1 clinical trial at Gosford and Wyong hospitals in New South Wales, according to a Monday filing with the Australian bourse.The clinical research organization now expects to obtain final site approvals and activation by April, the filing said. Patient enrollment will start once these approvals are received. Human ethics approval for additional trial sites in Australia, Hong Kong, and South Korea is expected in the coming months.The RAC-010 clinical trial aims to assess the safety, tolerability, and pharmacokinetics of RC220 alone and in combination with doxorubicin in patients with solid tumors, the filing stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","XKO.AU","BK7067","BK7508","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2519813701","title":"Friday’s HotCopper Trends: Race kicks off trials, Tivan in Timor-Leste | March 14, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519813701","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519813701?lang=en_us&edition=fundamental","pubTime":"2025-03-14 09:59","pubTimestamp":1741917540,"startTime":"0","endTime":"0","summary":"The ASX has been up as much as 0.45% at 7,783 points, breaking its Week 11 losing streak on the back of a rally in gold stocks.Materials has been the best performing sector, up 1.85%, followed by Utilities, up 1.4%, and Industrials, up 0.7%. Energy has been the worst performer, down 0.9%, followed by Telecommunication, down 0.33%, and Information Technology, down 0.25%.Race Oncology  has been the most watched on HotCopper forums today after the company received ethics approval for its Phase One trial in adult solid tumour patients.Also heavily discussed has been Liontown Resources ; the long-followed battery minerals producer today released its half year results. The company has maintained a strong cash position with $193 million in the bank.Also trending: Tivan , which was awarded copper-gold exploration licenses in Timor-Leste. The approval has seen Tivan jump 8.5% today.You’re up to date — see you a little later for HotCopper’s Market Close.Join the discussion: See what’s trending r","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/fridays-hotcopper-trends-race-kicks-off-trials-tivan-in-timor-leste-march-14-2025-2025-03-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","LTR.AU","RAC.AU","BK7508","BK7504","BK7067"],"gpt_icon":0},{"id":"2519899968","title":"Race Oncology Receives Ethics Committee's Nod for Phase 1 Trial of Cancer Treatment Drug Candidate; Shares Rise 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2519899968","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519899968?lang=en_us&edition=fundamental","pubTime":"2025-03-14 08:01","pubTimestamp":1741910491,"startTime":"0","endTime":"0","summary":"Race Oncology  said that the Bellberry Human Research Ethics Committee approved its phase 1 trial of its reformulated bisantrene drug candidate RC220, in combination with doxorubicin for patients with solid tumors, according to a Friday filing with the Australian bourse.The open-label, multi-center trial aims to evaluate the safety, tolerability, and pharmacokinetic profile of the drug candidate as a standalone treatment and in combination with doxorubicin.It will start at Southside Cancer Care Centre in New South Wales this month, pending institutional approval, with up to nine additional sites to follow, the filing said.Stage 1 of the trial involves dose escalation to determine the maximum tolerated combined dose  in up to 33 patients, the filing added.Stage 2 will expand to patients who haven't received anthracyclines, confirming safety and exploring endpoints like cardioprotection and anticancer effects, the company said.Shares of the company rose 9% in recent Friday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","RAC.AU"],"gpt_icon":0},{"id":"2519962378","title":"Race Oncology approved for Phase I trial for chemotherapeutic treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2519962378","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519962378?lang=en_us&edition=fundamental","pubTime":"2025-03-14 07:10","pubTimestamp":1741907400,"startTime":"0","endTime":"0","summary":"Race Oncology Ltd  has been approved for its Phase One trial of its chemotherapeutic candidate RC220 to treat people with solid tumours.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.The approval – granted by the Bellberry Human Research Ethics Committee  – allows Race to push ahead with a trial to test the tolerability, safety, and pharmacokinetics of RC220 bisantrene on its own and together with doxorubicin.Race is collaborating with Cancer Care Foundation on this trial. The approval means the Foundation’s main site, which is based at the Southside Cancer Care Centre in New South Wales, will soon be able to begin enrolling patients under the guidance of Principal Investigator Dr Mahmoud Alam.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/race-oncology-approved-for-phase-i-trial-for-chemotherapeutic-treatments-2025-03-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["RAC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2518239532","title":"Race Oncology's (ASX:RAC) investors will be pleased with their stellar 240% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2518239532","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518239532?lang=en_us&edition=fundamental","pubTime":"2025-03-10 06:03","pubTimestamp":1741557794,"startTime":"0","endTime":"0","summary":"Race Oncology Limited  shareholders might be concerned after seeing the share price drop 25% in the last quarter. But that scarcely detracts from the really solid long term returns generated by the company over five years. We think most investors would be happy with the 240% return, over that period. So while it's never fun to see a share price fall, it's important to look at a longer time horizon. Only time will tell if there is still too much optimism currently reflected in the share price. While the returns over the last 5 years have been good, we do feel sorry for those shareholders who haven't held shares that long, because the share price is down 60% in the last three years.So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/race-oncologys-asx-rac-investors-220314718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2517578469","title":"Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2517578469","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517578469?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:35","pubTimestamp":1741152914,"startTime":"0","endTime":"0","summary":"Race Oncology  signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.Its shares rose 3% on market close on Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","XAO.AU","BK7067","XKO.AU","XJO.AU","BK7508"],"gpt_icon":0},{"id":"2517939073","title":"BRIEF-Race Oncology Executes A$8.6M Contract","url":"https://stock-news.laohu8.com/highlight/detail?id=2517939073","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517939073?lang=en_us&edition=fundamental","pubTime":"2025-03-05 09:16","pubTimestamp":1741137407,"startTime":"0","endTime":"0","summary":"BRIEF-Race Oncology Executes A$8.6M Contract March 5 (Reuters) - Race Oncology Ltd RAC.AX:RACE EXECUTES A$8.6M CONTRACT TO SUPPORT PHASE 1 TRIAL OF RC220 IN SOLID TUMOUR PATIENTSFurther company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN12W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","RAC.AU","BK7508"],"gpt_icon":0},{"id":"2517984985","title":"Race Oncology Ltd - Race Executes a$8.6M Contract to Support Phase 1 Trial of Rc220 in Solid Tumour Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984985","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984985?lang=en_us&edition=fundamental","pubTime":"2025-03-05 05:58","pubTimestamp":1741125537,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN12W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2506561257","title":"3 ASX Penny Stocks With Market Caps Larger Than A$100M To Watch","url":"https://stock-news.laohu8.com/highlight/detail?id=2506561257","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506561257?lang=en_us&edition=fundamental","pubTime":"2025-01-28 15:05","pubTimestamp":1738047904,"startTime":"0","endTime":"0","summary":"The Australian market has seen mixed performances recently, with the ASX200 closing slightly down amid sector shifts and reactions to global developments. Despite these fluctuations, certain investment opportunities continue to attract attention, particularly in sectors showing resilience or growth potential. Penny stocks, though often seen as a niche area, can offer intriguing prospects for investors when they are backed by strong financials and fundamentals.Overview: Plenti Group Limited operates in the fintech lending and investment sector in Australia, with a market capitalization of A$133.58 million.ASX:PLT Financial Position Analysis as at Jan 2025. Overview: Race Oncology Limited is a clinical stage biopharmaceutical company dedicated to developing treatments for cancer patients, with a market cap of A$217.14 million.Operations: The company's revenue is derived entirely from its operations in Australia, amounting to A$4.00 million.Race Oncology Limited, a clinical stage biopharm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-asx-penny-stocks-market-070504424.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","BK7070","BK7067","XKO.AU","BK7045","BK7095","LBL.AU","BK7062","CAF.AU","BK7132","RAC.AU","PLT.AU","XJO.AU","ANG.AU","BK7023","HLO.AU","GTN.AU","VLS.AU","BK7088","IGL.AU","EVO.AU","SKS.AU","SHA.AU","BK7077","BK7055","XAO.AU","SVM.AU","BK7093","BK7508"],"gpt_icon":0},{"id":"2505236712","title":"Orix's Stake Sale in Greenko Energy to Provide Additional Capital, S&P Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2505236712","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505236712?lang=en_us&edition=fundamental","pubTime":"2025-01-22 18:50","pubTimestamp":1737543008,"startTime":"0","endTime":"0","summary":"Orix's  planned sale of its entire stake in Greenko Energy Holdings for $1.46 billion will provide a temporary capital buffer for the company, S&P Global Ratings said in a Tuesday release.The transaction, which includes convertible notes worth $731 million for energy production business AM Green, will improve the Japan-based diversified finance company's risk-adjusted capital  ratio by more than 0.6 percentage points, the rating agency said.The company may use the additional capital for future business growth, according to S&P.However, S&P said the improvement may be temporary, with the RAC ratio being steady at 9.5% to 10% in the next two years, especially given the company's investment history in riskier growth areas.Price : $3310.00, Change: $+28, Percent Change: +0.85%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2489008481","title":"ASX Market Close: Index pares gains as Bitcoin cracks US$100,000 | December 5, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2489008481","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489008481?lang=en_us&edition=fundamental","pubTime":"2024-12-05 14:09","pubTimestamp":1733378940,"startTime":"0","endTime":"0","summary":"The ASX200 closed up 0.15% at 8,474 points.Bitcoin broke through US$100,000 for the very first time after climbing 6.9%. The OG cryptocurrency is now much more accessible, given the advent of crypto ETFs – and this is perhaps contributing to its phenomenal price rise.IT has been the strongest performing sector, up 1.1%, followed by Real Estate, up 0.8% and Discretionary, up 0.75%. Energy has been the biggest loser, down 0.75%, followed by Materials, down 0.4%, and Health Care, down 0.2%.Global Lithium closed up xxx% after joining the ranks of lithium minersturning to other metalsas the great lithium rerate makes another project unviable. The company has acquiredOctava Minerals’ Talga Project, prospective for gold and base metals.Race Oncology  closed up 12.06% on news it had submitted the human ethics application package for its Phase 1 solid tumour trial.Perseus Mining  closed up 6.46% on the release of a drilling update from the recently acquired Nyanzaga Gold Project in Tanzania. Me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-pares-gains-as-bitcoin-cracks-us100000-december-5-2024-2024-12-05/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["09008","BOE.AU","03008","BK7506","BK1611","BK4601","BK7067","BK4594","PMT.AU","BK7083","03042","BK7504","PRU.AU","03439","BK4585","BK7095","09439","BK7508","PLS.AU","09042","RAC.AU","BK7507","83042","GL1.AU","BK7511","RIO.AU","OCT.AU","BK7104","BK4588"],"gpt_icon":1},{"id":"2489288171","title":"3 ASX biotech shares rocketing 10% to 26% on BIG news!","url":"https://stock-news.laohu8.com/highlight/detail?id=2489288171","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489288171?lang=en_us&edition=fundamental","pubTime":"2024-12-05 09:28","pubTimestamp":1733362088,"startTime":"0","endTime":"0","summary":"Three ASX biotech shares are setting the bar high today. The companies have grabbed investor interest today, with each releasing promising news. And this is sending them racing ahead of the 0.2% gains","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/05/3-asx-biotech-shares-rocketing-10-to-26-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4585","LU1894683348.USD","LU1894683264.USD","XAO.AU","BK7508","BIG","LDX.AU","BK4220","LU2346227817.USD","BK7067","BK4208","BK4588","IIQ.AU","CMS","RAC.AU","BK7124","BK7126","BK4114","LU2637428348.USD"],"gpt_icon":0},{"id":"2489217813","title":"Race Oncology Files Ethics Application for Solid Tumor Trial; Shares Rise 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489217813","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489217813?lang=en_us&edition=fundamental","pubTime":"2024-12-05 08:34","pubTimestamp":1733358846,"startTime":"0","endTime":"0","summary":"Race Oncology  filed an application with the Bellberry Human Research Ethics Committee for a phase 1 trial investigating the use of the RC220 bisantrene in combination with doxorubicin to potentially treat solid tumors, according to a Thursday filing made with the Australian bourse.Once approved, the biopharmaceutical firm will activate the first trial site in New South Wales, with an additional 10 sites to follow, the filing said.Patient recruitment for the trial is scheduled for the first quarter of next year, the filing added.The company's shares surged past 9% in recent Thursday trade.Price : $1.41, Change: $+0.12, Percent Change: +9.33%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK4125","AUD","LU0345774631.USD","LU0426417589.USD","LU2238339852.HKD","LU1043141123.HKD","LU0994945656.USD","LU0426412945.USD","BK7508","BK7067"],"gpt_icon":0},{"id":"2488185351","title":"Queensland Pacific Metals' Unit Finalizes Contracts for Power Station, Gas Pipeline; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2488185351","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488185351?lang=en_us&edition=fundamental","pubTime":"2024-12-04 10:23","pubTimestamp":1733278998,"startTime":"0","endTime":"0","summary":"Queensland Pacific Metals  said its unit QPM Energy has finalized the agreements relating to its Townsville Power Station  dispatch rights contract and North Queensland Gas Pipeline  gas transport and storage services contract, according to a Wednesday filing with the Australian bourse.In August, QPM Energy signed a ten-year contract with RATCH Australia Corporation  to secure dispatch rights for 100% of TPS's 160MW gas turbine capacity once current arrangements expire.The gas producer also signed a ten-year contract with NQGP for gas transport and storage services, the filing said.The company maintains the key commercial terms announced in August, which stated that the agreements will significantly reduce fixed operating charges, strengthening the company's financial position and accelerating its gas production growth plans.QPM Energy also said that annual fixed charges under the agreements are expected to drop by 83% compared to current terms and the new terms will boost the company'","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4084","BK7067","XAO.AU","BK4234","XKO.AU","BK7508","QPM.AU","TPS.AU","BK7095","XJO.AU","RAC.AU","PW"],"gpt_icon":0},{"id":"2487056223","title":"ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest","url":"https://stock-news.laohu8.com/highlight/detail?id=2487056223","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487056223?lang=en_us&edition=fundamental","pubTime":"2024-11-29 11:09","pubTimestamp":1732849787,"startTime":"0","endTime":"0","summary":"An Australian biotech that counts former Macquarie Group Ltd  CEO Allan Moss and Platinum Asset Management fund among its shareholders is planning an ASX initial public offering  next year.  According to The Australian, HaemaLogiX has hired Jefferies and Ord Minnett to assist in its preparations to become an ASX healthcare stock in the second quarter of the new year.  The biotech hopes to raise about $50 million in the ASX IPO.  As a private company, HaemaLogiX has previously raised $24.1 million. It is currently undertaking a pre-ASX IPO capital raise. It hopes to raise between $15 million and $20 million by mid-December.  What is HaemaLogiX?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/29/asx-ipo-watch-aspiring-healthcare-stock-has-attracted-former-macquarie-ceo-to-invest/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7005","BK7511","MQG.AU","RAC.AU","BK7062","BK7046","CCL.AU","BK7508","XAO.AU","MAC.AU","BK7067","HMC.AU","REIT.AU","XKO.AU","BK7162","XJO.AU","GYG.AU","IPO","BK7137","BK7110","REIT"],"gpt_icon":0},{"id":"2485486986","title":"2 ASX healthcare shares having a stellar run today","url":"https://stock-news.laohu8.com/highlight/detail?id=2485486986","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485486986?lang=en_us&edition=fundamental","pubTime":"2024-11-21 10:52","pubTimestamp":1732157578,"startTime":"0","endTime":"0","summary":"ASX healthcare shares are currently in the red on Thursday, with theS&P/ASX 200 Health Care Index(ASX: XHJ) down 0.2% and the broaderS&P/ASX 200 Index(ASX: XJO) 0.18% lower. However, two ASX healthcar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/21/2-asx-healthcare-shares-having-a-stellar-run-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["RNA","BK4585","BK7508","SIG.AU","BK7103","BK4139","XJO.AU","BK7067","RAC.AU","BK4505","BK4588"],"gpt_icon":0},{"id":"2485857154","title":"ASX Market Update: Index pares gains to trade flat in the afternoon | November 21, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485857154","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485857154?lang=en_us&edition=fundamental","pubTime":"2024-11-21 10:17","pubTimestamp":1732155420,"startTime":"0","endTime":"0","summary":"The ASX200 has been down 0.1% at 8,317 points.The local bourse pared early gains and has been trading flat in the afternoon.The brent crude oil price has steadied at around US$73 per barrel as US crude stockpiles grow for the third week in a row.Energy has been the strongest sector, up 0.65%, followed by Financials, up 0.4% and Utilities, up 0.33%. Discretionary has lost the most ground, down 0.77%, followed by Real Estate, down 0.5%.Vulcan Energy  has been up 5.8% on news its inked a deal with one of the world’s largest chemical producers, BASF. Vulcan will collaborate on the development of a renewable geothermal heat project to supply BASF with baseload heat.Sayona Mining  has been down 8% after completing a capital raise of around $40 million at a 16% discount to yesterday’s closing price.Race Oncology  has been up 2.2% on news its successfully completed an FTO-targeted drug discovery program at Monash University’s Fragment Platform . The company says 39 unique protein-binding molec","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-pares-gains-to-trade-flat-in-the-afternoon-november-21-2024-2024-11-21/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7504","BK7095","BK7067","SYA.AU","RAC.AU","VUL.AU"],"gpt_icon":0},{"id":"2485107336","title":"Race Oncology Completes Drug Discovery Program at Monash University; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485107336","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485107336?lang=en_us&edition=fundamental","pubTime":"2024-11-21 09:38","pubTimestamp":1732153121,"startTime":"0","endTime":"0","summary":"Race Oncology  completed a drug discovery program targeting the Fat and Obesity associated  protein at Monash University's Fragment Platform, according to a Thursday filing with the Australian bourse.The program used nuclear magnetic resonance screening to identify 39 chemical candidates that bind specifically to the FTO protein, the filing said.The FTO protein is a key regulator in ribonucleic acid  epigenetics. Loss of control of RNA epigenetics is linked to several cancers and metabolic diseases.The identification of the chemical candidates by Race Oncology provides a platform for developing new FTO-targeting drugs, the filing said.Race Oncology plans to advance these candidates into a hit-to-lead medicinal chemistry program, though a final decision has not yet been made on progressing this expensive phase.The company's shares rose almost 3% in recent Thursday trade.Price : $1.40, Change: $+0.04, Percent Change: +2.94%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","RNA","BK7067","BK4505","BK4585","LU1043141123.HKD","LU0994945656.USD","BK7508","LU0426417589.USD","BK4125","BK4588","AUD","LU0345774631.USD","LU0426412945.USD","LU2238339852.HKD","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAC.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAC.AU\",market:\"AU\",,,undefined,":[]}}